Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels

JAMA: The Journal of the American Medical Association

Volumn 262, Issue 1, 1989, Pages 53-56

  Ballantyne, Christie M ^a   Podet, Ethan J ^a   Patsch, Wolfgang P ^a   Harati, Yadollah ^a   Appel, Vicki ^a   Gotto, Antonio M ^a   Young, James B ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOSPORIN; LIPOPROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ATHEROSCLEROSIS; HUMAN; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AMYOTROPHIC LATERAL SCLEROSIS; ARTERIOSCLEROSIS; CHOLESTEROL; CYCLOSPORINS; DOUBLE-BLIND METHOD; FASTING; HUMAN; LIPOPROTEINS; LIPOPROTEINS, LDL; LIVER; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; RANDOM ALLOCATION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRIGLYCERIDES;

EID: 0024353758     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1989.03430010065032     Document Type: Article

References (41)

1. ACT Newsline. Alexandria, Va: American Council on Transplantation; 1989.
2. Bieber CP, Hunt SA, Schwinn A, et al. Complications in long-term survivors of cardiac transplantation. Transplant Proc. 1981;13:207-211.
3. Gunnarsson R, Lofmark R, Nordlander R, Nyquist O, Groth CG. Acute myocardial infarction in renal transplant recipients: incidence and prognosis. Eur Heart J. 1984;5:218-221.
4. McGrath BP, Ledingham JGG. Cardiovascular complications after renal transplantation. In: Morris PJ, ed. Kidney Transplantation. Principles and Practice. New York, NY: Grune & Stratton; 1979:313-333.
5. Ibels LS, Alfrey AC, Weil R. Hyperlipidemia in adults, pediatric and diabetic renal transplant recipients. Am J Med. 1978;64:634-642.
6. Cattran DC, Steiner G, Wilson DR, Fenton SSA. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med. 1979;91:554-559.
7. Goldstein S, Duhamel G, Laudat MH, et al. Plasma lipids, lipoproteins and apolipoproteins AI, AII and B in renal transplanted children: what risk for accelerated atherosclerosis? Nephron. 1984; 38:87-92.
8. Hess ML, Hastillo A, Mohanakumar T, et al. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation. 1983;68(suppl 2):94-101.
9. Ballantyne CM, Jones PH, Payton-Ross C, et al. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc. 1987;19:60-62.
10. Becker DM, Markakis M, Sension M, et al. Prevalence of hyperlipidemia in heart transplant recipients. Transplantation. 1986;44:323-325.
11. Chan MK, Varghese Z, Persaud JW, Fernando ON, Moorhead JF. The role of multiple pharmacotherapy in the pathogenesis of hyperlipidemia after renal transplantation. Clin Nephrol. 1981; 15:309-313.
12. Jackson JM, Lee HA. The role of propranolol therapy and proteinuria in the etiology of post renal transplantation hyperlipidemia. Clin Nephrol. 1982;18:95-103.
13. Donatsch P, Abisch E, Homberger M, et al. A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay. 1981;2:19.
14. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29:1075-1080.
15. Nagele U, Hagele EO, Sauer G, et al. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem. 1984;22:165-174.
16. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg 2++ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
18. Specific Proteins: Discover the Power of Protein Analysis. Brea, Calif: Beckman Institute Inc; 1987. Bulletin 6227.
19. Hollister LE, Wright A. Diurnal variation of serum lipids. J Atherosclerosis Res. 1965;5:445-450.
20. Folsom AR, Kuba K, Luepker RV, Jacobs DR, Frantz ID. Lipid concentrations in serum and EDTA-treated plasma from fasting and nonfasting normal persons, with particular regard to high-density lipoprotein cholesterol. Clin Chem. 1983; 19:505-508.
21. Stamler JS, Vaughn DE, Rudd MA, et al. Cyclosporine-mediated hypercholesterolemia in cardiac transplant patients. J Am Coll Cardiol. 1988;11:153A.
22. Gurecki J, Warty V, Sanghvi A. The transport of cyclosporine in association with plasma in heart and liver transplant patients. Transplant Proc. 1985;17:1997-2002.
23. Kahan BD. Immunosuppressive therapy with cyclosporine for cardiac transplantation. Circulation. 1987;75:40-56.
24. Princen HMG, Meijer P, Hofstee B, Havekes LM, Kuipers F, Vonk RJ. Effects of cyclosporin A (CsA) on LDL-receptor activity and bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat. Hepatology. 1987;7:1109. Abstract.
25. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256:3110-3116.
26. Harris KPG, Russell GI, Parvin SD, Veitch PS, Walls J. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. Br Med J. 1986;292:16.
27. Versluis DJ, Wenting GJ, Derkx FHM, Schalekamp MADH, Jeekel J, Weimar W. Who should be converted from cyclosporine to conventional immunosuppression in kidney transplantation, and why. Transplantation. 1987;44:387-389.
28. Grimm RH, Leon AS, Hunninghake DB, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann Intern Med. 1981;94:7-11.
29. Day JL, Metcalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J. 1982;284:1145-1148.
30. Nichols AJ, Catto GRD, Edward N, Engeset J, Macleod M. Accelerated atherosclerosis in long-term dialysis and renal-transplant patients: fact or fiction. Lancet. 1980;1:276-278.
31. Thompson J, Eich D, Ko D, et al. Hypercholesterolemia as a marker of early coronary artery disease post cardiac transplantation. Circulation. 1987;76(suppl 4):167. Abstract.
32. Gao SZ, Schroeder JS, Alderman EL, Hunt SA, et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation. 1987;76(suppl 5):V-56-V-61.
33. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987;76:827-834.
34. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc. 1987;19:19-25.
35. Alonso DR, Starek PK, Minick CR. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol. 1977;87:415-435.
36. Kappos L, Patzold U, Dommasch D, et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis: results of the German multicenter study. Ann Neurol. 1988;23:56-63.
37. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988;318:663-670.
38. Brynskov J, Binder V, Riis P, et al. Cyclosporine in inflammatory bowel disease. Transplant Proc. 1988;20(suppl 4):309.
39. Lipid Research Clinics Program. Lipid research clinics coronary primary prevention trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
40. Keogh A, Day R, Critchley L, DugginG, Baron D. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc. 1988;20:27-30.
41. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988;318:47-48.